More recently, PBMC-derived TG2 mRNA levels were significantly associated with MS clinical and radiological progression [3], thus supporting further investigations regarding the role of TG2 expression as a potential biomarker for disease progression in patients with MS. Here, TGM2 is linked to myeloid sarcoma.